Results 11 to 20 of about 53,515 (238)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study [PDF]

open access: yesBMC Cancer, 2021
Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking.
Stéphane Dalle   +18 more
doaj   +5 more sources

Ipilimumab [PDF]

open access: yesReactions Weekly, 2019
En definitiva, el desarrollo del ipilimumab, el primer anticuerpo contra un punto de control inmunológico, ha demostrado su eficacia en el control de diversos tumores malignos, ha iniciado el renacer de la inmunooncología que está revolucionando el ...
Jantus-Lewintre, Eloisa   +1 more
core   +5 more sources

Ipilimumab in melanoma

open access: yesExpert Review of Anticancer Therapy, 2012
Ipilimumab is a fully human monoclonal antibody directed against the cytotoxic T-lymphocyte antigen-4 receptor. Blocking cytotoxic T-lymphocyte antigen-4 signaling has been shown to enhance T-cell activation and to amplify T-cell-mediated immunity. Ipilimumab, either as a single agent or in combination with gp100 vaccination, significantly prolonged ...
Pruis, M., Specenier, Pol
core   +9 more sources

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. [PDF]

open access: yesPLoS ONE, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Caroline J Voskens   +35 more
doaj   +3 more sources

Ipilimumab-Induced Neutropenia in Melanoma

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD   +3 more
doaj   +2 more sources

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

open access: yesCase Reports in Oncology, 2016
Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma.
Marcus Messmer   +6 more
doaj   +2 more sources

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

open access: yesFrontiers in Oncology, 2014
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable ...
Anna M. Leung   +10 more
doaj   +2 more sources

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2018
Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with high
Shelby L Kubicki   +2 more
doaj   +2 more sources

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

open access: yesJournal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi   +8 more
doaj   +2 more sources

Ipilimumab: its potential in non-small cell lung cancer

open access: yesTherapeutic Advances in Medical Oncology, 2012
Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is ...
Pascale Tomasini   +3 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy